Where does Cancer Hospital, Chinese Academy OF Medical Sciences rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Cancer Hospital, Chinese Academy OF Medical Sciences ranks #28,330 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

What is Cancer Hospital, Chinese Academy OF Medical Sciences's Innovation Score?

Cancer Hospital, Chinese Academy OF Medical Sciences has an Innovation Score of 41.7 out of 100 (top 32% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Cancer Hospital, Chinese Academy OF Medical Sciences's patent grant rate increasing or decreasing?

Cancer Hospital, Chinese Academy OF Medical Sciences's recent grant velocity is +200% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for Cancer Hospital, Chinese Academy OF Medical Sciences's patents?

Cancer Hospital, Chinese Academy OF Medical Sciences's patents average 8.9 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Cancer Hospital, Chinese Academy OF Medical Sciences

Q: How many patents does Cancer Hospital, Chinese Academy OF Medical Sciences hold?

Cancer Hospital, Chinese Academy OF Medical Sciences holds 9 US utility patents granted between 2017 and 2025, spanning 11 technology areas.

Q: What technology areas does Cancer Hospital, Chinese Academy OF Medical Sciences focus on?

Cancer Hospital, Chinese Academy OF Medical Sciences's top technology area is C12Q (Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes) with 4 patents, ranking #1,001 of 2,502 assignees active in that subclass. Grants appear in 11 CPC subclasses total.

Q: How is the Cancer Hospital, Chinese Academy OF Medical Sciences patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO PatentsView assignee record - 9 granted patents across 11 technology areas, recorded in grant years 2017–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C12Q (Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Micr).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Cancer ranks #28,330 of 49,997 tracked US assignees by granted-patent volume, with 9 patents across 11 technology areas.

#28,330
of 49,997 US assignees by volume: Top 32%
by Innovation Score (41.7/100): 8.9
avg claims per patent: +200%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R28330 · Foreign Corporation #28,330 · 9 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-PAR · TYPE-FRNCORP · VEL-SURGE · BOOK-FULL

GRANTS-MICRO 9 grants
MID-PACK #28,330/49,997
PHOTO-FINISH Calyxia
CPC-FOCUS C12Q · 11 areas
INNOV-PAR 41.7/100
CLAIMS-PAR 8.9 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-SURGE +200% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Calyxia (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Cancer’s 41.7 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 8.0 pts (19%) Velocity 16.7 pts (40%) Breadth 11.7 pts (28%) Claim depth 5.3 pts (13%)

Qualcomm Incorporated · highest

85
Cancer Hospital… · this assignee

42
3D Lighting… · lowest

7

What this shows Cancer's Innovation Score is 41.7/100 (top 32% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Cancer?

Each dot is one of Cancer’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Cancer’s own 8.9 claims/patent is at or below the 13.3 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Cancer vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Cancer's grants concentrate

Cancer Hospital, Chinese Academy OF Medical Sciences is a focused PatentsView assignee: 11 CPC subclasses with 44.4% of grants classified under C12Q (Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Micr). Peak complete grant year is 2024 (4 grants) versus a trough of 1 in 2017. By volume, Cancer sits between Calyxia and Car-ber Investments Inc..

Cancer's three-year grant acceleration

Cancer Hospital, Chinese Academy OF Medical Sciences shows 5 grants in 2022–2024 against only 2 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Calyxia

9
Cambridge Glycosc…

9
Came S p A

9
Canadian Solar Ma…

9
Capartis

9
Capella Therapeut…

9
Capital Normal Un…

9
Car-ber Investmen…

9
Cancer Hospital C… ◀

9

What this shows Cancer holds 9 patents at rank #28,324, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Cancer

By rank, the assignees closest to #28,324 in granted patent volume.

Leaders in C12Q (Measuring OR Testing Processes Involving Enzymes)

Other assignees with the most granted patents in Cancer's primary technology class.

Cancer's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

42 Top 32% higher than 68% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2017–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2017–2019 baseline. Full figures in the table below.

View data table

Cancer Hospital, Chinese Academy OF Medical Sciences patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2017	1	11.1%
2019	1	11.1%
2021	1	11.1%
2023	1	11.1%
2024	4	44.4%
2025partial year	1	11.1%

Which technologies does Cancer Hospital, Chinese Academy OF Medical Sciences patent most?

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 4

G16H - Healthcare Informatics, i.e. Information AND Communication Technology [ICT] Specially Adapted FOR THE Handling OR Processing OF Medical OR Healthcare Data 4

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 3

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 3

C07K - Peptides 2

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 2

G06T - Image Data Processing OR Generation, IN General 2

A61N - ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy 2

G16B - Bioinformatics, i.e. Information AND Communication Technology [ICT] Specially Adapted FOR Genetic OR Protein-related Data Processing IN Computational Molecular Biology 1

G06V - Image OR Video Recognition OR Understanding 1

Y02A - Technologies FOR Adaptation TO Climate Change 1

Top 11 of 11 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Cancer Hospital, Chinese Academy OF Medical Sciences's patent record in context - here's where to go next.

Cancer Hospital, Chinese Academy OF Medical Sciences's lead technology class is C12Q (Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Micr), 44.4% of its portfolio - see every assignee active in that class. Explore C12Q
Ranked #28,330 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Cancer Hospital, Chinese Academy OF Medical Sciences against Calyxia, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 41.7/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.